Background
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Current therapies lead to high remission rates, but many patients relapse, often with the involvement of the brain and spinal cord – the Central Nervous System (CNS). Specific CNS-directed treatments limit these CNS relapses but do not eliminate them. Additionally, these CNS-directed treatments have severe short- and long-term side effects, particularly in children.
